Skip to main content
Gastric oncology

Stomach (Gastric) Cancer

Staging, biomarkers, perioperative therapy, and gastrectomy

HER2, PD-L1, CLDN18.2, and MSI/MMR are different tests. When they matter depends on the stage of disease.

Early gastric cancer can feel like ordinary indigestion — the question I hear most is how long to keep taking acid medicine alone. I do not lock perioperative sequencing before staging laparoscopy and peritoneal cytology when indicated. Gastric cancer care starts with accurate staging; many locally advanced tumors receive chemotherapy around the time of surgery. Gastrectomy includes the appropriate lymph nodes. Symptoms that persist or worsen need endoscopy. Biomarkers guide systemic therapy especially in advanced disease: HER2, PD-L1, and CLDN18.2 mainly shape metastatic drug choice, while MSI/MMR can matter earlier. Laparoscopic or robotic gastrectomy is considered only when the same cancer operation can be done safely.

Stomach (Gastric) Cancer · educational illustration

Educational schematic. Some structures may be simplified or emphasized for clarity; not an exact anatomical depiction.

© Cengiz Dibekoğlu — illustrative; not for unauthorized use

Figure summary

  • Labeled on this figure: Esophagus · Stomach · Duodenum.
  • Related figures on this page: Diagnosis, Treatment, Operations, Robotic.

Figure labels (English)

  • Esophagus
  • Stomach
  • Duodenum

Educational figures

Tap a figure to enlarge. These English illustrations mirror the Turkish hub gallery for this condition.

  • Diagnosis

    Educational schematic. Some structures may be simplified or emphasized for clarity; not an exact anatomical depiction.

    © Cengiz Dibekoğlu — illustrative; not for unauthorized use

  • Treatment

    Educational schematic. Some structures may be simplified or emphasized for clarity; not an exact anatomical depiction.

    © Cengiz Dibekoğlu — illustrative; not for unauthorized use

  • Operations

    Educational schematic. Some structures may be simplified or emphasized for clarity; not an exact anatomical depiction.

    © Cengiz Dibekoğlu — illustrative; not for unauthorized use

  • Robotic

    Educational schematic. Some structures may be simplified or emphasized for clarity; not an exact anatomical depiction.

    © Cengiz Dibekoğlu — illustrative; not for unauthorized use

  • Perioperative pathway

    Neoadjuvant then surgery then adjuvant when indicated.

  • Biomarkers by stage

    HER2 / PD-L1 / CLDN18.2 mainly shape advanced systemic choices.

  • MSI/MMR

    Separate clinical meaning, including earlier settings.

  • Minimally invasive options

    Laparoscopic / robotic gastrectomy in selected cases.

What to know

  • How biomarkers affect treatment

    Key note inside

    HER2, PD-L1 CPS, and CLDN18.2 mainly influence advanced/metastatic drug choice. MSI/MMR may matter in localized disease as well. Not every marker is mandatory at every stage.

    • MSI/MMR → stage-dependent meaning
    • HER2 / PD-L1 / CLDN18.2 → mainly advanced disease
    • Timing is set in tumor board
  • Staging before locking sequence

    CT staging, endoscopy, and — when indicated — staging laparoscopy with cytology prevent operating into unresectable peritoneal disease.

  • Surgery types

    Subtotal versus total gastrectomy depends on tumor location and oncologic margins. Lymphadenectomy extent follows oncologic standards, not incision size.

  • Nutrition is part of treatment

    Prehabilitation, feeding routes, and vitamin supplementation after gastrectomy are planned with the resection — not left as an afterthought.

  • When major resection is not offered

    Key note inside

    Unresectable spread or performance status that cannot tolerate major surgery changes the goal toward systemic therapy and symptom control — stated honestly.

What happens next

What patients notice — and which warning signs need urgent care

Oncologic surgery7 chapters

Evidence

Scientific sources

Show sources · 3

International guidelines for gastric cancer staging, multimodal therapy, and surgical pathways.

  1. 1. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upESMO · 2022 · DOI: 10.1016/j.annonc.2022.07.004Open source →
  2. 2. NCCN Guidelines — Gastric CancerNCCN · Current versionOpen source →
  3. 3. ESMO Gastrointestinal Cancer Guidelines (topic hub)ESMO · Living / eUpdateOpen source →

Last reviewed: 21 August 2026. Links go to publisher pages.

Appointment / info

Pathology with biomarker reports, endoscopy notes, and staging imaging accelerate an honest perioperative plan.

This page is for education. It is not medical advice and does not replace a visit with your physician.

Medical editor: Assoc. Prof. Cengiz Dibekoğlu, MD · English patient-education hub.